Network-based computational method, with the emphasis on biomolecular interactions and biological data integration, has succeeded in drug development and created new directions, such as drug repositioning and drug combination. Drug repositioning, that is finding new uses for existing drugs to treat more patients, offers time, cost and efficiency benefits in drug development, especially when in silico techniques are used. microRNAs (miRNAs) play important roles in multiple biological processes and have attracted much scientific attention recently. Moreover, cumulative studies demonstrate that the mature miRNAs as well as their precursors can be targeted by small molecular drugs. At the same time, human diseases result from the disordered interplay of tissue-and cell lineage-specific processes. However, few computational researches predict drug-disease potential relationships based on miRNA data and tissue specificity. Therefore, based on miRNA data and the tissue specificity of diseases, we propose a new method named as miTS to predict the potential treatments for diseases. Firstly, based on miRNAs data, target genes and information of FDA (Food and Drug Administration) approved drugs, we evaluate the relationships between miRNAs and drugs in the tissue-specific PPI (protein-protein) network. Then, we construct a tripartite network: drug-miRNA-disease Finally, we obtain the potential drug-disease associations based on the tripartite network. In this paper, we take breast cancer as case study and focus on the top-30 predicted drugs. Regorafenib is likely to be a truly effective drug, worthy of our further study. It further follows that our method miTS is effective and practical for predicting new drug indications, which will provide potential values for treatments of complex diseases.
Introduction
The identification of therapeutic approaches for the treatment of cancer is an arduous, costly, and often inefficient process. By conservative estimates, it now takes over 15 years and $800 million to $1 billion to bring a new drug to market 1 . Drug repositioning, which is the discovery of new indications for existing drugs, is an increasingly attractive mode of therapeutic discovery. A repositioned drug does not need the initial six to nine years required for the development of new drugs, but instead goes directly to preclinical testing and clinical trials, thus reducing risk and costs 2 . Repositioning drugs has been implemented in several ways. One of the well-known examples is sildenafil citrate, which was repositioned from a hypertension drug to a therapy for erectile dysfunction 3 . Drugs treat diseases by targeting the proteins related to the phenotypes arising from the disease. However, drug development does not accurately follow the "one gene, one drug, one disease" principle, which has been challenged in many cases 4 and the traditional drug repositioning methods by accident makes it hard to satisfy medical needs by successfully repositioning a large number of existing drugs. Computational methods are able to solve this question by high-level integration of available biological data and elucidation of unknown mechanisms.
In recent years, systems biology continues to make important progress to solve fundamental problems in biology and leading to practical applications in medicine and drug discovery 5 . Network-based computational systems biology emphasizes the interactions among biomolecules and highlights the network concept. Typically, a network comprises a set of nodes and edges, and is described by graph theory in a mathematical manner 6 . A node can be a biological molecule, for example, gene, RNA, protein, metabolite, and pathway. A node can also be at the phenotype level such as disease and drug. An edge can represent the complex interaction between two nodes such as protein-protein interaction, drug-disease therapeutic relationship, drug-protein target relationship, and so on. The accumulation of different high-throughput biology data, such as gene expression data, miRNA expression data and drug-target data, has made the reconstruction of biomolecular and cellular networks possible. Cheng et al.
built a bipartite graph composed of the approved drugs and proteins linked by drug target binary associations, and relied on a supervised network-based inference method to predict drug-target interactions 7 . Chen et al. constructed a general heterogeneous network which comprised drugs and proteins linked by protein-protein sequence similarity, drug-drug chemical similarity, and the known drug-target interaction 8 . Yeh et al. 9 developed a network flow approach for identifying potential target proteins, which have a strong influence on disease genes in the context of biomolecular networks. The biomolecular networks are weighted by degree of co-expression of interacting protein pair.
More recently, many studies have demonstrated that drugs can regulate microRNA (miRNAs) expression and mature miRNAs as well as their precursors can be targeted by small molecular drugs 10, 11, 12, 13 . For example, Miravirsen (SPC3649) is the first miRNA-targeted drug in clinical trials, which can successfully inhibit miR-122 expression that is required by hepatitis C virus replication 14 . The expression levels of 32 miRNAs (significant up-regulation of 22 miRNAs and down-regulation of 10 miRNAs) were changed after the treatment of trichostatin A in human breast cancer cell lines 15 . miRNAs are non-coding small RNAs (∼23 nucleotides) that downregulate gene expression at the post transcriptional level by inhibiting translation or initiating mRNA degradation and are dysregulated in most of human cancers 16 . Increasingly evidences have demonstrated that miRNAs play significant roles in many important biological processes, such as cell growth 17 , cellular signaling 18 , tissue development 19 and disease process 20 . Although only approximately 2000 miRNAs exist in humans, they regulate 30% of all genes. miRNAs have been identified to play a crucial role in various human disease, especially in cancers. Therefore, targeting miRNAs with drugs will provide a new type of therapy for complex diseases 21 and a new direction for drug repositioning. However, few computational researches predict drug-disease relationships based on miRNA data. Moreover, many genes with tissue-specific expression and function are expected to underlie many human diseases 22, 23 . Therefore, in this study, we propose a new method based on miRNA data and tissue specificity of diseases, named as miTS, to predict potential drugs for diseases. The framework of miTS is shown in Figure 1 . Firstly, we download miRNA expression data of diseases from TCGA 24 , miRNA-target gene relationship data from three experimentally validated databases: miRecords 25 , miRTarbase 26 and TarBase
27
, and the drug-target gene data from Drugbank 28 and KEGG 29 . Secondly, we select differentially expressed miRNAs of diseases based on a threshold and preprocess the target information of FDA approved drugs. Thirdly, we evaluate the relationships between miRNAs and drugs in the tissue-specific PPI network. And then, we construct a tripartite network: drug-miRNA-disease. Finally, we obtain the potential drug-disease associations based on the tripartite network. In this paper, we take breast 
Method Screening differentially expressed miRNAs
In order to obtain the differentially expressed miRNAs of breast cancer, we first filter the miRNAs expression data downloaded from TCGA. For a miRNA r , we use formula (2) to calculate its Z -score .
Where R is the RPKM value of miRNA r ; mean ( ) r and ( ) r  represent mean value and standard deviation of r , respectively. Then we choose Z -score =1.645
(p-value = 0.05) as threshold to screen differentially expressed miRNAs. Finally, we get a total of 40 differentially expressed miRNAs of breast cancer (see Table 1 ). In Table 1 , the miRNAs marked by "*" represent they have connections with breast cancer in HMDD. We find 34 of 40 (85%) differentially expressed miRNAs are related with breast cancer, which indicates that miRNAs associated with breast cancer tend to be highly expressed in breast cancer patients. Then, we choose the 34 miRNAs marked by "*" in Table 1 for further study. The miRNAs marked by "*" represent they have relationship with breast cancer in HMDD.
Construct drug-miRNA-disease tripartite network
The relationship between a miRNA and a drug is derived by measuring the correlation between their target sets. Because miRNA target genes, drug target genes and protein-protein interaction (PPI) networks remain largely incomplete, we calculate the distance between two modules based on the shortest path in incomplete networks 33 . 
Results

CTD benchmark verification
In our study, we choose breast cancer as case, the drug-breast cancer associations are ranked in descending order according to their scores. In order to verify the accuracy of our results, we use the drug-breast cancer relationships data in Comparative Toxicogenomics Database (CTD) 34 as benchmark. As shown in Figure 3 , we give the precision curves of predicted drug-breast cancer relationship results. For each given threshold, the precision of our method is calculated by formula (5).
Where P represents the number of predicted drug-disease pairs; CTD P represents the number of drug-disease pairs, which can be found in CTD database.
In Figure 3 , we give the precision curves of predicted drug-breast cancer pairs at different top-x%. From the figure, we find the higher the associations ranking, the higher the accuracy. Hence, for the breast cancer, we choose top 30 drugs for further analysis. The top 30 drugs related to breast cancer are shown in Table 2 . We validate the 30 drugs by CTD database and find 11 (36.7%) of them are marked as "therapeutic (T)", which means that they have a highly correlation with breast cancer.
In addition, we find 14 of the rest 19 drugs also have connections with breast cancer in CTD database with inference score over 0 and they are marked as "Ref" in Table 2 .
That is to say, there are 83.3% (25/30) drugs can be found in the CTD database and we predict five potential drugs for breast cancer (DB08871, DB00031, DB08813, DB08896, and DB06813, marked as boldface in Table 2 ). Pralatrexate (DB06813) is an anti-cancer drug. It is the first drug approved as a treatment for patients with relapsed T-cell lymphoma 41 . Pralatrexate results in increased activity of CASP3 protein, which has been found to be necessary for normal brain development as well as its typical role in apoptosis, where it is responsible for chromatin condensation and DNA fragmentation 42 .
Clinical evaluation
Tenecteplase (DB00031) is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line and used as a thrombolytic drug. Nielsen VG et al. 43 to study whether tissue-type plasminogen activator (tPA) in plasma obtained from patients with breast cancer, lung cancer, pancreatic cancer and colon cancer is less than that obtained from normal individuals.
The results show that tissue-type plasminogen activator-induced fibrinolysis in breast cancer, lung cancer, pancreatic cancer and colon cancer patients is enhanced.
Sumiyoshi K et al. 44 found that the increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer may play a role in tumor progression and metastasis. Although we have not found the relationship between tenecteplase (DB00031) and breast cancer through the literatures, the drug had the similar effects as nadroparin 45 . Therefore, we infer that tenecteplase is likely to have effect on breast cancer.
KEGG pathway functional enrichment analysis
In this section, we will further make KEGG pathway enrichment analysis on five potential drugs and their associated disease. KEGG (http://www.kegg.jp/ or http://www.genome.jp/kegg/) is an encyclopedia of genes and genomes 46 . Its primary goal is to assign functional meanings to genes and genomes both at the molecular and higher levels. Thus, drugs or diseases can be associated with certain pathways through their related genes. If a drug has overlapping KEGG pathways with a disease, the drug and the disease may have great relevance. That is, the drug may treat or cause the disease by acting on the overlapping pathways.
We use DAVID 47 , 48 functional annotation tool for KEGG pathway enrichment
analysis. DAVID provides a comprehensive set of functional annotation tools for investigators to understand biological significance of a large number of genes. For any given gene list, DAVID is able to visualize genes on BioCarta & KEGG pathway maps, identify enriched biological themes, especially GO terms, and so on. Therefore, we use DAVID to identify overlapping KEGG pathways between potential drugs and breast cancer. The p-value is set to be less than 0.05.
We find Nadroparin and Regorafenib have 4 and 15 overlapping KEGG pathways with breast cancer, respectively. The details are shown in Table 3 . From Table 3 For drug Tenecteplase, we find one function enrichment pathway: "hsa04610:
Complement and coagulation cascades". In 2016, based on the microarray data of GSE3467 from Gene Expression Omnibus(GEO) database, Yu J et al. 51 identified the differentially expressed genes (DEGs) between 9 PTC samples and 9 normal controls.
The purpose was predicted key genes and pathways in papillary thyroid carcinoma.
Their results showed that the highly expressed genes in papillary thyroid carcinoma were mainly enriched on the "hsa04610: Complement and coagulation cascades" functional pathway. As for Pralatrexate, because it has only two targets: DHFR and TYMS, it has few related KEGG pathways. That is the main reason that Pralatrexate has no overlapping KEGG pathways with breast cancer at present.
Overlapping genes between enriched KEGG pathways
To further analyze our results, for Eribulin mesylate, Tenecteplase and Pralatrexate, Due to the incompleteness of data, there may be some biases in our method. With the continuous improvement of data, our method miTS will find more effective drugs for disease treatment. All in all, our research reveals a promising perspective to predict drug-disease relationships and seeks new opportunities for drug repositioning.
